Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer
cells from dividing so they stop growing or die. Combining more than one drug may kill more
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating
patients who have relapsed low-grade non-Hodgkin's lymphoma.